MétaCan
Menu
Back to cohort
Record W2034458673 · doi:10.1158/1535-7163.targ-11-b50

Abstract B50: A phase I study of various administration schedules for RO4929097 (R) with multi-parameter assessment (pharmacokinetics [PK] and primary tumor xenograft [XG]) in patients (pts) with advanced solid cancers.

2011· article· en· W2034458673 on OpenAlexaff
Albiruni RA Razak, Philippe L. Bédard, Benoît You, Devang Panchal, Eric X. Chen, S. Percy Ivy, Wenjiang Zhang, Suzanne Kamel‐Reid, Nhu‐An Pham, Tong Zhang, Sebastién J. Hotte, Michael Reedijk, Momiko Shimizu, Laurie Ailles, Christine Haines, Amit M. Oza, Ming‐Sound Tsao, Lillian L. Siu

Bibliographic record

VenueMolecular Cancer Therapeutics · 2011
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicCancer, Hypoxia, and Metabolism
Canadian institutionsJuravinski Cancer CentrePrincess Margaret Cancer Centre
Fundersnot available
KeywordsMedicinePharmacokineticsNauseaVomitingDosingHypophosphatemiaPharmacologyCancerAdverse effectInternal medicineOncologyGastroenterology

Abstract

fetched live from OpenAlex

Abstract Background: Dysregulated Notch signalling has been implicated in a variety of cancers. R is a potent and selective inhibitor of -secretase, a key enzyme in Notch signalling. Phase I data demonstrated R to be tolerable but PK profile revealed auto-induction with repeated dosing at high doses (Tolcher et al. ASCO 2010). The primary aim of this study is to determine the optimal regimen of R using alternative dosing schedules. Its secondary aim is to establish mouse XG from tumor biopsies to enable correlative biomarker research. Methods: Pts with advanced solid tumors were enrolled in one of 6 different schedules and starting doses of R. Serial PK samples were collected on Day 1 and at steady state. Mandatory pre and post treatment tumor biopsies were procured if medically safe and implanted subcutaneously into NOD-SCID mice for propagation in up to 4 serial generations. Tumor DNA from second XG passage was analyzed using the Sequenom OncoCarta Panel v1.0 (SOCP). Results: To date, 24 pts have been enrolled. PK data are available for 21 pts, summarized in Table 1. The maximum tolerable dose for schedules C-F has not been reached. Commonest adverse events (AE) of all grades with at least possible attribution to R were fatigue (n=14), nausea (13), hypophosphatemia (11), anorexia (9) and diarrhoea (8). Grade 3/4 AEs consisted of hypophosphatemia (n=2), lymphopenia (2), vomiting (1) and QTc prolongation (1). Data on engraftment are available from biopsies of 18 pts (18 pre and 16 post treatment samples). Primary tumor sites included gastrointestinal (n=6), breast (4), melanoma (2), ovarian (2), pancreatic (1), neuroendocrine (1), parotid (1) and lung cancers (1). In pre treatment biopsies, the rate of initial engraftment was 12/18 (67%); while in post treatment biopsies, the rate of initial engraftment was 14/16 (88%). Further passages (2nd and 3rd) from viable engrafted cancers demonstrated a 100% engraftment rate. The SOCP analyses were carried out in 9 different XG models with mutations detected in 4 (KRAS [n=3] and BRAF mutations), all of which were from metastatic colon cancers. Conclusions: Preliminary PK evaluation demonstrated auto-induction of R in schedules A and B (concordant with prior data), but to a lesser degree in schedules C, D & E. It is unclear whether this observation was due to the lower administered doses of R or the alternative schedules employed. This study demonstrated the ability to generate mouse XG models from different tumor histologies using core biopsies, with a mean engraftment rate of 78% at first implantation. We also confirmed the feasibility of detecting point mutations in cancers using SOCP platform on XG specimens. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2011 Nov 12-16; San Francisco, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2011;10(11 Suppl):Abstract nr B50.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.005
Threshold uncertainty score0.017

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0010.000
Science and technology studies0.0000.001
Scholarly communication0.0010.001
Open science0.0010.000
Research integrity0.0010.003
Insufficient payload (model declined to judge)0.0050.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.024
GPT teacher head0.324
Teacher spread0.300 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2011
Admission routes1
Has abstractyes

Explore more

Same venueMolecular Cancer TherapeuticsSame topicCancer, Hypoxia, and MetabolismFrench-language works237,207